I would prefer PYC to own and develop the entire pipeline, but license out the manufacture and sales of each drug, and also the ph3 trials in the US - the FDA is a beast that needs experience to negotiate.
Managing trials in the US will take a huge effort in resources and know how, and will require a huge injection of cash. I’m not saying PYC can’t undertake this, but I am saying that it would be most efficiently achieved via license. Just my view.
It will also take a company with global reach to maximize the true sales potential of our drugs if successful.
My point was that NEU sat in the doldrums for years, and it took only one indication to massively rerate the company. That took a long time, but shows it is achievable for a small Aussie biotech.
PYC is not far from reporting on efficacy, which will, in my view, completely change the markets view of our worth.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)